Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IlluminOss Appoints Avila as CEO

This article was originally published in Clinica

Executive Summary

IlluminOss Medical has brought in more commercial expertise to its senior executive team with the appointment of Manny Avila as CEO. Avila has over 20 years’ experience in medical device sales, operations and business management. He was most recently Global Vice-President of sales and marketing at OmniGuide and prior to that, he served as VP of commercial operations, surgical solutions Europe for Covidien. Avila’s appointment comes three months after IlluminOss tapped former Zimmer executive Clive Ridgewell as VP of sales. The Rhode Island-based company has developed a minimally invasive system – comprising a light curable polymer contained in an expandable balloon catheter – for treating complex fractures. The firm is currently conducting US trials of the product for FDA approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel